TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04059666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational
Description: Cow's milk-based Infant Formula with whey protein-lipid concentrate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Cow's milk-based Infant Formula
Study: NCT04634110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: At day 1, all patients will be started on brigatinib 90 mg daily for 7 days, before escalating to 180 mg daily thereafter as tolerated.
Study: NCT01338428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced AAA Sexual Assault Resistance Education
Description: Resistance Program: 4x3-hour units. Unit 1 (Assess) accurate assessment of sexual assault risk. Provides: empirically-based information on situational and (male) behavioural danger cues; practice identifying risk and counteracting it. Unit 2 'Acknowledge\[ment\]' of risk when present. Includes: women's sexual rights; emotional barriers; tactics used by coercive men; practice. Unit 3 (Act) includes: assessing whether or not an escape is possible; research evidence on the effectiveness of resistance strategies; physical self-defense training. Unit 4 applies content to longer term relationships covering: comfort talking about sexuality, identification of sexual values, practices beyond intercourse, and articulation of relationship goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brochure
Description: Current 'standard of care' at Canadian universities. Invitation to take and read brochures on sexual assault selected from those available on their Canadian university campus. All sites' brochures include general information on sexual assault and 'date-rape' drugs and post-rape legal and medical advice. The research assistant (RA) will ask the participants to take brochures, read them over, and to ask any questions they may have. Questions will be answered in a group setting and the participant will take home any brochures that she selected. Interaction between participants and the RA on the topic will be limited to 10-15 minutes and will be audio recorded for verification.
Study: NCT00994838

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reduced calorie diet
Description: 10% reduction in total daily calories (≈ 300 kcal reduction) from carbohydrates and fat from the usual daily energy consumption
Study: NCT02563496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: Tafenoquine tablet is supplied as film-coated tablet (100 mg, 150 mg, 200 mg and 300 mg) and fast-dispersing film coated tablet (50 mg).
Study: NCT03805828

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational program on parenting stress and coping mechanism
Description: The educational program will deliver as a one-day event in four sessions: (1)background of autism spectrum disorder(ASD) and coping mechanism,(2) targeting communication and social difficulties among ASD children using coping mechanism,(3) targeting behavior problems among ASD children using coping mechanism, and (4) stress management as coping mechanism. The contents of the educational program deliver through the use of PowerPoint slides, Whiteboard and marker, practical exercise, video clips followed by group discussion and provision a hard copy booklet containing all items which were supposed to discuss. As well as each session will approximately be taken one hour. Each group will consist of 10 participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational program on parenting stress and coping mechanism
Description: The educational program will deliver as a one-day event in four sessions: (1)background of autism spectrum disorder(ASD) and coping mechanism,(2) targeting communication and social difficulties among ASD children using coping mechanism,(3) targeting behavior problems among ASD children using coping mechanism, and (4) stress management as coping mechanism. The contents of the educational program deliver through the use of PowerPoint slides, Whiteboard and marker, practical exercise, video clips followed by group discussion and provision a hard copy booklet containing all items which were supposed to discuss. As well as each session will approximately be taken one hour. Each group will consist of 10 participants.
Study: NCT00908752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brivanib
Description: Tablets, Oral, 200 mg, once daily, until disease progression or toxicity
Study: NCT02563496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: Tafenoquine tablet is supplied as film-coated tablet (100 mg, 150 mg, 200 mg and 300 mg) and fast-dispersing film coated tablet (50 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: Tafenoquine tablet is supplied as film-coated tablet (100 mg, 150 mg, 200 mg and 300 mg) and fast-dispersing film coated tablet (50 mg).
Study: NCT00908752

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Brivanib Placebo
Description: Tablets, Oral, 0 mg, once daily, until disease progression or toxicity

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE Therapy
Description: Trans-Arterial Chemo-Embolization Therapy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TACE Therapy
Description: Trans-Arterial Chemo-Embolization Therapy
Study: NCT01693484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG (Indocyanine Green)
Description: Diagnostic drug used for visualisation of blood perfusion in various tissues.Administered intravenously, 2X: 1X prior to anesthesia, and 1X after tourniquet on operative extremity has been released for at least 15 minutes. When excited by laser light source, it subsequently emits at a near infrared frequency.
Study: NCT02849925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sealants to arrest microcavitated caries.
Description: Carious lesions will be treated by minimally invasive dentistry by the use of sealants instead of eliminating carious tissues and using conventional restorative materials.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sealants to arrest microcavitated caries.
Description: Carious lesions will be treated by minimally invasive dentistry by the use of sealants instead of eliminating carious tissues and using conventional restorative materials.
Study: NCT02563496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: Tafenoquine tablet is supplied as film-coated tablet (100 mg, 150 mg, 200 mg and 300 mg) and fast-dispersing film coated tablet (50 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: Tafenoquine tablet is supplied as film-coated tablet (100 mg, 150 mg, 200 mg and 300 mg) and fast-dispersing film coated tablet (50 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Subjects may receive chloroquine according to local/national treatment guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Subjects may receive chloroquine according to local/national treatment guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Subjects may receive chloroquine according to local/national treatment guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Subjects may receive chloroquine according to local/national treatment guidelines.
Study: NCT03150979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provision of a cane
Description: The participants will receive a single-point cane and will be instructed to use it all the time during locomotion. Weekly, they will receive a phone call, to ensure that they are using the cane and to clarify any doubts. A home visit may be conducted, if necessary.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The control group will be instructed to to perform stretching of the lower limb muscles daily and keep their daily activities, without the use of a cane. They will also receive weekly phone calls, to ensure similar level of attention to that of the the participants in the experimental group.
Study: NCT01760122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ypeginterferon alfa-2b
Description: sc, qw, 48 weeks.
Study: NCT02563496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Subjects may receive chloroquine according to local/national treatment guidelines.
Study: NCT01947465

Intervention type: BIOLOGICAL
Intervention: Hepatitis A vaccine and tetanus vaccine
Description: Hepatitis A and/or tetanus vaccination will be given to participants in all group on day 0. All monovalent active hepatitis A vaccinations and all vaccines containing tetanus toxoid available in Switzerland may be used in the study

Intervention type: BIOLOGICAL
Intervention: Hepatitis A vaccine and tetanus vaccine
Description: Hepatitis A and/or tetanus vaccination will be given to participants in all group on day 0. All monovalent active hepatitis A vaccinations and all vaccines containing tetanus toxoid available in Switzerland may be used in the study
Study: NCT01760122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: sc, qw, 48 weeks.
Study: NCT02322879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: First Treatment Period
Description: (duration: 14 days) Subjects will be randomized to receive either of the 2 interventions (4 grams of solid acetaminophen formulation for two weeks vs. 4 grams of solid acetaminophen formulation + 70 mg/kg/day of liquid propylene glycol)
Study: NCT02322879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: First Treatment Period
Description: (duration: 14 days) Subjects will be randomized to receive either of the 2 interventions (4 grams of solid acetaminophen formulation for two weeks vs. 4 grams of solid acetaminophen formulation + 70 mg/kg/day of liquid propylene glycol)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washout
Description: (duration: 14 days) At the end of the First intervention period all participants will enter a washout period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washout
Description: (duration: 14 days) At the end of the First intervention period all participants will enter a washout period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second Treatment Period
Description: (duration: 14 days) At the end of the washout period, participants will receive the alternative intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second Treatment Period
Description: (duration: 14 days) At the end of the washout period, participants will receive the alternative intervention.
Study: NCT00671671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Small Molecule Agent (PF-868554)
Description: Study drug will be administered 700mg BID in the fed state for three days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Small Molecule Agent (PF-868554)
Description: Study drug will be given 450mg BID for a duration of 10 days.
Study: NCT05405959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: The Kinesio Tex Gold FP (Kinesio Tex Tape, Kinesio Holding Corporation, Albuquerque, NM, USA) was used. It was waterproof, porous and adhesive, had a width of 5 cm and a thickness of 0.5 mm. The same brand of tape was used in both groups.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Kinesio Tape
Description: The Kinesio Tex Gold FP (Kinesio Tex Tape, Kinesio Holding Corporation, Albuquerque, NM, USA) was used. It was waterproof, porous and adhesive, had a width of 5 cm and a thickness of 0.5 mm. The same brand of tape was used in both groups.
Study: NCT03536546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Peer Mentor Intervention
Description: A Veteran Peer research assistant will have contact with a study participant once in person in the emergency department at enrollment, and up to 6 times after enrollment over the course of 2 months. Participants will receive brief advice from a peer. Brief advice content will be based on strengths-based discussions with participants regarding their drinking and personal goals and preferences. Participants will also receive a resource pamphlet on alcohol and other health issues. Follow-up contact will be made by phone. The content of the follow-up peer intervention will be based on the manual developed by the study team to address strengths-based intervention topics.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Advice
Description: Participants will receive brief substance use advice from a non-peer research staff member in the emergency department. Brief advice content will mirror standard care practices currently provided in VHA when a patient endorses hazardous drinking behaviors. Participants will also receive a resource pamphlet on alcohol and other health issues.
Study: NCT03715205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered as an intravenous (IV) infusion every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
Study: NCT00995072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebivolol and metoprolol succinate
Description: Subjects randomized to treatment Arm A will receive nebivolol 5 mg once daily for 12 weeks. After 12 weeks, double blind therapy will be discontinued and patients will undergo a wash-out period of study therapy over 2 weeks. Subjects randomized to treatment Arm A will then receive metoprolol succinate 100 mg once daily. Subjects will continue double blind therapy for a total duration of 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol succinate and nebivolol
Description: Subjects randomized to treatment Arm B will receive metoprolol succinate 100mg once daily for 12 weeks. After 12 weeks, double blind therapy will be discontinued and patients will undergo a wash-out period of study therapy over 2 weeks. Subjects randomized to treatment Arm B will then receive nebivolol 5 mg once daily. Subjects will continue double blind therapy for a total duration of 12 weeks.
Study: NCT03063294

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online Toolkit
Description: The online toolkit provides a set of tools that clinics can use to improve their care coordination processes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Toolkit
Description: The online toolkit provides a set of tools that clinics can use to improve their care coordination processes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distance-based coaching
Description: The distance-based coach supports included clinics in carrying out a quality improvement project focused on care coordination, either using the online toolkit or other resources determined by the clinic.
Study: NCT04196426

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition education intervention about osteoporosis and calcium
Description: The intervention is designed and developed based on the Intervention Mapping Process and the Health Belief Model. Topics of the intervention include: the importance of osteoporosis and risk factors, role of calcium in bone health and controlling the disease, calcium recommendations and sources, role of vitamin D and physical activity in calcium absorption and bone health, and how to identify calcium-rich foods in the locality and prepare meals with local calcium-rich foods. A recipe booklet containing recipes using local calcium-rich foods will be given to the participants after the end of the two nutrition lessons. Interactive activities are incorporated in each lesson to encourage the participation of participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention about osteoporosis and calcium
Description: The intervention is designed and developed based on the Intervention Mapping Process and the Health Belief Model. Topics of the intervention include: the importance of osteoporosis and risk factors, role of calcium in bone health and controlling the disease, calcium recommendations and sources, role of vitamin D and physical activity in calcium absorption and bone health, and how to identify calcium-rich foods in the locality and prepare meals with local calcium-rich foods. A recipe booklet containing recipes using local calcium-rich foods will be given to the participants after the end of the two nutrition lessons. Interactive activities are incorporated in each lesson to encourage the participation of participants.
Study: NCT04663022

Intervention type: OTHER
Intervention: Dunn's sensory profile questionnaire
Description: all children will complete the Dunn Sensory Profile questionnaire

Intervention type: OTHER
Intervention: Dunn's sensory profile questionnaire
Description: all children will complete the Dunn Sensory Profile questionnaire
Study: NCT04115111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab in monotherapy as second line treatment
Study: NCT03758170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: An intravenous bolus dose of dexamethasone given prior to surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: An intravenous bolus dose of dexamethasone given prior to surgery.
Study: NCT01911377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline for Injection
Study: NCT03260868

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine, 300 units per milliliter (U/mL)
Description: Self-administered subcutaneous injection using prefilled pen once daily for 24 weeks. Dose titration to achieve fasting self-monitoring of plasma glucose (SMPG) level between 80 and 130 milligram per deciliter (mg/dL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine, 300 units per milliliter (U/mL)
Description: Self-administered subcutaneous injection using prefilled pen once daily for 24 weeks. Dose titration to achieve fasting self-monitoring of plasma glucose (SMPG) level between 80 and 130 milligram per deciliter (mg/dL).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
Description: Subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
Description: Subcutaneous injection.
Study: NCT00826306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Educational Materials
Description: In the experimental arm, the intervention is the video-based patient educational material on sunscreen. In the active comparison arm (control arm), the comparison intervention is written patient educational material on sunscreen.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Educational Materials
Description: In the experimental arm, the intervention is the video-based patient educational material on sunscreen. In the active comparison arm (control arm), the comparison intervention is written patient educational material on sunscreen.
Study: NCT01763879

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The PCV-VCV group
Description: During the PCV period, the inspiratory pressure will be adjusted to deliver a TV of 6 mL/kg (predicted body weight) to the patient's dependent lung. During the VCV period, the patient's dependent lung will be ventilated with a TV of 6 mL/kg (PBW). Whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The VCV-PCV group
Description: During the PCV period, the inspiratory pressure will be adjusted to deliver a TV of 6 mL/kg (predicted body weight) to the patient's dependent lung. During the VCV period, the patient's dependent lung will be ventilated with a TV of 6 mL/kg (PBW). Whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
Study: NCT04049318

Intervention type: OTHER
Intervention: Education+ exercise (delivered digitally)
Description: The intervention consisted of a digital, structured and individualized treatment program for people with hip or knee OA (Joint Academy®; www.jointacademy.com). The program consists of neuromuscular exercises appropriately adjusted to each patient in regard to degrees of complexity and difficulty, continuous access to and dialogue with a physiotherapist through a chat function, and/or telephone , and information in the form of text or video lessons (with quizzes on the material after each episode) on subjects related to OA, OA symptoms and its management.

Intervention type: OTHER
Intervention: Education+ exercise (delivered digitally)
Description: The intervention consisted of a digital, structured and individualized treatment program for people with hip or knee OA (Joint Academy®; www.jointacademy.com). The program consists of neuromuscular exercises appropriately adjusted to each patient in regard to degrees of complexity and difficulty, continuous access to and dialogue with a physiotherapist through a chat function, and/or telephone , and information in the form of text or video lessons (with quizzes on the material after each episode) on subjects related to OA, OA symptoms and its management.